FCS

AllianceBernstein and Integreon Win Gold at Financial Communications Society's 29th Annual "Star Gala"

Retrieved on: 
Tuesday, May 9, 2023
Maintenance, Partnership, Education, Financial services, Marketing, AllianceBernstein, Spiegel (US retailer), Website, AB, Research, Organization, Creative, Digital asset management, DAM, ADA, Ziegfeld Theatre (1969), FCS, Financial adviser

NASHVILLE, Tenn. and FARGO, N.D., May 9, 2023 /PRNewswire/ -- AllianceBernstein ("AB"), a leading global investment management and research firm, and Integreon, a trusted global provider of creative, business and legal outsourced services, placed first in the 29th Annual Financial Communications Society (FCS) Portfolio Awards in the 'Business-to-Business Website' category.

Key Points: 
  • Held on May 4 at the Ziegfeld Ballroom in New York City, the FCS Annual Portfolio Awards honored 81 financial services organizations.
  • These organizations were judged by a panel of senior marketing executives from industry-leading institutions and agencies for creative excellence in communications.
  • "We are proud of the incredible work Integreon put into helping us build AllianceBernstein's US Retail Financial Advisor Site," said AB's Co-Head of Global Marketing Pinki Mehta.
  • Founded in 1967, the FCS is a national, not-for-profit organization dedicated to improving professional standards in financial marketing communications through a mission of community, education, and philanthropy.

Florida Cancer Specialists & Research Institute President & Managing Physician Lucio Gordan, MD Featured Speaker at Nationwide Oncology Event

Retrieved on: 
Thursday, May 4, 2023
Ion exchange, Genetics, ION, AmerisourceBergen, Policy, Pathology, Genomics, Science, Pulitzer Prize, MD, Patient, Physician, Knowledge, GPO, Oncology, FCS, Nursing

FORT MYERS, Fla., May 4, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio Gordan, MD is among the national experts and physician leaders at the ION Exchange 2023 this week in San Diego who will share the latest clinical, operational and business insights to advance the quality of cancer care in community settings.

Key Points: 
  • Lucio Gordan, MD & Siddhartha Mukherjee, MD, discuss new developments in oncology resulting from genetic discoveries.
  • Dr. Gordan will participate in a keynote session with noted medical oncologist, biologist, Rhodes scholar and Pulitzer Prize winning author Siddhartha Mukherjee, MD .
  • Dr. Gordan said, "Breakthroughs in the science of genetics are transforming our ability to deliver truly personalized cancer care.
  • Exchange 2023 is an event series hosted by ION Oncology Practice Network, a part of AmerisourceBergen and the largest physician service organization and group purchasing organization (GPO) specializing in the support of community oncology nationwide.

CJ Biomaterials' Amorphous Polyhydroxyalkanoate (PHA) Added to FDA's Inventory of Food Contact Substances

Retrieved on: 
Wednesday, May 3, 2023
Home composting, Food, Federal Food, Drug, and Cosmetic Act, FCN, Accor, Organization, NatureWorks, PHA, Agency, Compost, CJ CheilJedang, TUV, FDA, Environment, FCS, Biopolymer, Safety, Thermoplastic, Medical device

FDA listing clears the way for CJ Biomaterials' amorphous PHA to be used in the manufacture of food contact materials sold in the US

Key Points: 
  • Woburn, Massachusetts--(Newsfile Corp. - May 3, 2023) - Amorphous polyhydroxyalkanoate (PHA) produced by CJ Biomaterials, Inc., a division of South Korea-based CJ CheilJedang, is now included in the U.S. Food and Drug Administration Inventory of Effective Food Contact Substances (FCS).
  • Assigned Food Contact Notification (FCN) 2281, CJ Biomaterials' amorphous PHA, branded PHACT™ A1000P, can now be used to make packaging materials sold in the United States that come into contact with food, including rigid and flexible packaging, serviceware and other products.
  • CJ Biomaterials introduced its amorphous PHA in early 2022, and the biopolymer is already being used to develop various end products, including cosmetic containers .
  • "The inclusion of our amorphous PHA in the FDA Inventory of Effective Food Contact Substances marks a major milestone for CJ Biomaterials, and it underscores our commitment to providing innovative, sustainable solutions that benefit both our customers and the environment.

Florida Cancer Specialists & Research Institute Celebrates Opening of New Clinic Location in Clermont

Retrieved on: 
Tuesday, May 2, 2023
Operation, Cancer, Research, Pharmacy, Patient, Physician, PET/CT, Environment, FCS, Management, Hospital, MD

FORT MYERS, Fla., May 2, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the opening of its new clinic location in Clermont with a ribbon-cutting ceremony on Thursday, April 27, 2023.

Key Points: 
  • FORT MYERS, Fla., May 2, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the opening of its new clinic location in Clermont with a ribbon-cutting ceremony on Thursday, April 27, 2023.
  • The new facility at 1340 N. Hancock Road, Clermont, FL 34711 replaces the former location in Lake County.
  • FCS Chief Procurement Officer Paul Chadwick opened the ceremony, welcoming FCS physicians, senior leaders and community partners, including Clermont Mayor Tim Murray .
  • Patients will also have opportunities to participate in clinical trials research as well as care management services.

Medical Oncologists Elena Kruglyak, MD and Samarth Reddy, MD Join Florida Cancer Specialists & Research Institute

Retrieved on: 
Monday, May 1, 2023
Florida Atlantic University, Montefiore Medical Center, University, College, Wayne State University, The College of Medicine, Hematology, University of Illinois at Chicago, Research, Oncology, Assistant, MD, Patient, Physician, Medical Center, Internal medicine, Hospice, Sackler Faculty of Medicine, FCS, Prostate cancer, Nursing

FORT MYERS, Fla., May 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome two Board-certified medical oncologists to its Delray clinic in Palm Beach County.

Key Points: 
  • FORT MYERS, Fla., May 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome two Board-certified medical oncologists to its Delray clinic in Palm Beach County.
  • Elena Kruglyak, MD and Samarth L. Reddy, MD have joined the statewide practice, and are providing care to patients at 5130 Linton Blvd, Suite B4, Delray Beach, Florida 33484.
  • "Both of these physicians join us with impressive credentials," said Lucio N. Gordan, MD , FCS President & Managing Physician.
  • He has held academic appointments and currently serves as Assistant Professor for the College of Medicine at Florida Atlantic University.

Targeted Therapy Developed in FCS Clinical Trials Transforming Cancer Treatment For Adult Patients with Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Friday, April 28, 2023
Lymphoma, University of Florida Cancer and Genetics Research Complex, Abstract, Polatuzumab vedotin, Hematology, DLBCL, Non-Hodgkin lymphoma, FACP, Bone marrow, Cancer, Quality of life, Exposition, Hope, MD, Patient, Lymph, Clinical research, Drug development, FDA, Society, FCS, Safety, Pharmaceutical industry, Medical device

FORT MYERS, Fla., April 28, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) today released a case study outlining the evolution of a newly FDA-approved first-line therapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The treatment regimen combines use of Polatuzumab Vedotin (POLIVY®), a type of anti-body drug conjugate that is significantly improving outcomes in patients with this aggressive form of lymphoma. FCS actively participated in the phase 1, first in-human monotherapy trial for polatuzumab vedotin, as well as the pivotal phase 3 Polarix study which led to its FDA approval as first-line treatment.

Key Points: 
  • The treatment regimen combines use of Polatuzumab Vedotin (POLIVY®), a type of anti-body drug conjugate that is significantly improving outcomes in patients with this aggressive form of lymphoma.
  • Florida Cancer Specialists & Research Institute clinical trials contribute to FDA approval of Polatuzumab Vedotin.
  • According to Gustavo Fonseca, MD, FACP , FCS Director of Clinical Research, patients in the Phase 3 study achieved rapid and sustained improvements.
  • FCS offers more than 300 clinical trials at three Phase 1 Drug Development Units and 37 clinic locations across Florida.

ASCO Guideline Update for Anxiety and Depression Released

Retrieved on: 
Thursday, April 27, 2023
University of Florida Cancer and Genetics Research Complex, Volunteering, Depression, Education, Quality, CBT, MS, Science, Wastewater treatment, ASCO, Outline, American Society of Clinical Oncology, Patient, Standard of care, Quality of life, Clinical, Health, MBSR, Survivor, Mental health, Society, FCS, Nursing, Anxiety, Adult, Cancer, MD

FORT MYERS, Fla., April 27, 2023 /PRNewswire/ -- A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors. The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS, released updates to the pre-existing guidelines last revised in 2014 in the abstract: "Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update."

Key Points: 
  • Florida Cancer Specialists & Research Institute Medical Oncologist Barry Berman, MD, MS, Serves on ASCO Anxiety & Depression Update Expert Panel
    FORT MYERS, Fla., April 27, 2023 /PRNewswire/ -- A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors.
  • The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS , released updates to the pre-existing guidelines last revised in 2014 in the abstract: "Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update."
  • The panel also draws attention to statistics supporting how depression and anxiety in cancer patients tend to be overlooked and therefore untreated as they are considered a normal reaction to a cancer diagnosis.
  • The guidelines then outline options for treating depression and anxiety as separate issues, as well as offering guidance when both are experienced.

Richard McDonough, MD Honored for Patient Advocacy Efforts, Receives Dorothy Green Phillips Legacy Award at FLASCO Annual Gala

Retrieved on: 
Thursday, April 20, 2023
Neck, BCPS, Doctor of Pharmacy, Award, Cancer, EOM, Quality, Organization, Phillips, QUEST Honors Fellows Program, Patient, Physician, Gynecologic oncology, Health, FCS, Nursing, MD

FORT MYERS, Fla., April 20, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Richard McDonough, MD, is the recipient of the Florida Society of Clinical Oncology (FLASCO) 2023 Dorothy Green Phillips Legacy Award. The recognition was announced at FLASCO's Annual Gala held on April 14 in Orlando.

Key Points: 
  • FORT MYERS, Fla., April 20, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Richard McDonough, MD , is the recipient of the Florida Society of Clinical Oncology (FLASCO) 2023 Dorothy Green Phillips Legacy Award.
  • The recognition was announced at FLASCO's Annual Gala held on April 14 in Orlando.
  • The Award, named in honor of Dorothy Green Phillips, who retired in 2019 after serving as FLASCO Executive Director, is presented annually to a FLASCO member whose contributions leave a lasting legacy.
  • Phillips, known nationally as a trailblazer of innovative collaboration and a passionate advocate for cancer patients and providers, personally selected Dr. McDonough as this year's honoree.

New Study Evaluates Effects of Chemotherapy-Induced Myelosuppression for Extensive-Stage Small Cell Lung Cancer, Data from Florida Cancer Specialists & Research Institute

Retrieved on: 
Thursday, April 13, 2023
Neutropenia, Senior, Patient, FACP, American Society of Clinical Oncology, Bone marrow, Lung cancer, Aplastic anemia, Doctor of Philosophy, Pharmacist, SCLC, ASCO, Bone marrow suppression, Lymphocytopenia, G1 Therapeutics, Leukopenia, Risk, Anemia, Data, Thrombocytopenia, Society, FCS, Medical imaging, Medical device, MD

FORT MYERS, Fla., April 13, 2023 /PRNewswire/ -- A new study using data from Florida Cancer Specialists & Research Institute, LLC (FCS) evaluates the effects of chemotherapy-induced myelosuppression for extensive-state small cell lung cancer (ES-SCLC) in a real-world community oncology setting.

Key Points: 
  • FORT MYERS, Fla., April 13, 2023 /PRNewswire/ -- A new study using data from Florida Cancer Specialists & Research Institute, LLC (FCS) evaluates the effects of chemotherapy-induced myelosuppression for extensive-state small cell lung cancer (ES-SCLC) in a real-world community oncology setting.
  • The study, "Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices," was done in support of G1 Therapeutics and in collaboration with Xcenda.
  • ES-SCLC, considered a more aggressive form of metastatic small cell lung cancer, utilizes chemotherapy as a first-line treatment.
  • Patients experiencing myelosuppression are also at risk for developing additional medical issues resulting in delays in chemotherapy treatment until the myelosuppression is under control.

Battery Electric Train Deliveries on Track to Quadruple in 2023, Says IDTechEx

Retrieved on: 
Tuesday, April 11, 2023
Hydrogen, AKA, Paris, Paris Agreement, Atmosphere, Original equipment manufacturer, BEL, Bel, FC, Research, LFP, Bachelor, NMC, Kilowatt-hour, FCS, Chemistry, Fuel cell, Traction, Switcher, Mus, Lithium, Rail transport, Electric battery, Renewable energy

The new IDTechEx report " Battery Electric & Hydrogen Fuel Cell Trains 2023-2043 " assesses the global opportunities emerging for battery-electric and hydrogen fuel cell (FC) trains as energy storage technologies advance rapidly.

Key Points: 
  • The new IDTechEx report " Battery Electric & Hydrogen Fuel Cell Trains 2023-2043 " assesses the global opportunities emerging for battery-electric and hydrogen fuel cell (FC) trains as energy storage technologies advance rapidly.
  • Granular 20-year forecasts include train deliveries, battery demand (GWh), fuel cell demand (MW) and market value (US$ billion) across locomotive (BEL), multiple unit, and shunter trains.
  • Systems up to ~14MWh are being installed today in the largest trains, known as battery electric locomotives, or BELs.
  • To find out more about the new IDTechEx report "Battery Electric & Hydrogen Fuel Cell Trains 2023-2043", including downloadable sample pages, please visit www.IDTechEx.com/Train .